Last reviewed · How we verify

Talzenna (talazoparib)

Pfizer · FDA-approved active Verified Quality 72/100

Talzenna blocks PARP enzymes, which are involved in DNA repair, to prevent cancer cell growth.

Talzenna (talazoparib) is a small molecule Poly(ADP-Ribose) Polymerase Inhibitor developed by Pfizer, targeting PARP4. It was FDA-approved in 2018 for the treatment of germline BRCA-mutated, HER2-negative metastatic breast cancer. Talzenna is a patented medication with no generic manufacturers available. Key safety considerations include potential side effects such as anemia, fatigue, and neutropenia. As a PARP inhibitor, Talzenna works by blocking the action of PARP enzymes, which are involved in DNA repair.

At a glance

Generic nametalazoparib
SponsorPfizer
Drug classPoly(ADP-Ribose) Polymerase Inhibitor
TargetPoly [ADP-ribose] polymerase 4
Therapeutic areaOncology
PhaseFDA-approved
First approval2018
Annual revenue182

Mechanism of action

Talazoparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1 and PARP2, which play role in DNA repair. In vitro studies with cancer cell lines that harbored defects in DNA repair genes, including BRCA and BRCA 2, have shown that talazoparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, decreased cell proliferation, and apoptosis. Talazoparib anti-tumor activity was observed in human patient-derived xenograft breast cancer tumor models bearing mutated BRCA or mutated BRCA or wild-type BRCA and BRCA 2.

Approved indications

Common side effects

Key clinical trials

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity
SEC EDGARRevenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: